Sign In

Asya Grinberg

VP of Biologics Therapeutics

Asya Grinberg is a distinguished leader in biologics drug discovery and early development with a rich history of 20 years in the industry.

She excels in team leadership, forming strategic partnerships, and translating innovative scientific concepts into reality, focusing on clear goal-setting and effective communication to achieve outstanding outcomes.

Notable contributions to the field include involvement in the development of Reblozyl® and Sotatercept, along with multiple clinical assets and preclinical candidates across various stages of development.

Her expertise spans protein engineering, biologics generation, biology, analytical development, CMC, QC, and QA, all geared towards enhancing company value.

Having held key positions at renowned organizations like AstraZeneca, Dragonfly Therapeutics, and Acceleron Pharma, Asya's journey reflects a commitment to excellence and continuous learning.

She holds a Master's degree in Bioorganic Chemistry from Lomonosov Moscow State University and has studied at Universitaet des Saarlandes in Germany, showcasing a strong academic foundation.

As an advocate for innovation, Asya's portfolio boasts over 100 patents and scientific publications, establishing her as a thought leader in the industry.

Her approach emphasizes building a culture of creativity, empowerment, collaboration, and open communication, underpinned by values like honesty, integrity, and courage to explore new horizons.

Highlights

May 16 · linkedin

Brilliant to see science from our Biologics Engineering team at AstraZeneca front and center at PEGS Boston. Lots of interest in Sarav Rajan's presentation on our novel approach to screening native antibodies. We’re expanding our brilliant team in Boston. Connect with me at PEGS if you are curious.

Jan 17 · linkedin

Folks, If you are attending PepTalk this week, make sure you do not overlook the enlightening presentation by my glorious colleague Gilad Kaplan "Enhancement of Antibody Thermostability and Affinity by Computational Design in the Absence of Antigen" scheduled for this Friday at 9:35 am in the Antibody Design and Optimization workstream, which Gilad is also moderating. As Biologics drug developers we know first hand that engineering of the most potent, stable and successful biologic drug candidate requires significant time optimizing different properties of the molecule, like binding, stability and solubility. Machine Learning (ML) algorithms hold significant potential for faster optimization of Biologics and shortening the timelines to the clinic. Gilad's talk will present our approach to using ML to optimize antibodies for increased binding and thermostability without the need for any additional structural data. Tools such as these will allow high throughput optimization of antibodies early in the discovery phase, increasing the quality of drug candidates throughout selection.

Asya Grinberg
Add to my network

Location

Cambridge, Massachusetts, United States